Merck & Co.
Stock Forecast, Prediction & Price Target
Merck & Co. (MRK) stock Price Target by analysts
Merck & Co. (MRK) stock Price Target by analysts
Average Price Target
$134
Potential upside: 57.77%
Merck & Co. price prediction
What is Merck & Co. stock analysts` prediction?
Merck & Co. stock forecast: Based on 5 Wall Street analysts` predicted price targets for Merck & Co. in the last 3 months, the avarage price target is $134, with a high forecast of $NaN. The average price target represents a 57.77% change from the last price of $84.93.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Merck & Co. stock Price Target by analysts
Full breakdown of analysts given Merck & Co. price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Courtney Breen Bernstein | 0% 0/1 | 10 months ago | $110 29.51% upside | $100.69 | StreetInsider | Previous targets (0) |
Akash Tewari Jefferies | 0% 0/3 | 10 months ago | $148 74.26% upside | $98.36 | StreetInsider | Previous targets (2) |
Evan David Seigerman BMO Capital | 33.33% 1/3 | 11 months ago | $136 60.13% upside | $101.88 | StreetInsider | Previous targets (2) |
Trung Huynh UBS | 0% 0/1 | 12 months ago | $136 60.13% upside | $108.88 | TheFly | Previous targets (0) |
Carter Gould Barclays | 33.33% 1/3 | 12 months ago | $140 64.84% upside | $109.77 | TheFly | Previous targets (2) |
Akash Tewari Jefferies | 0% 0/3 | about 1 year ago | $147 73.08% upside | $113.49 | StreetInsider | Previous targets (2) |
Colin Bristow UBS | 50% 1/2 | about 1 year ago | $142 67.19% upside | $112.89 | Benzinga | Previous targets (1) |
Geoff Meacham Bank of America Securities | 50% 1/2 | about 1 year ago | $145 70.72% upside | $115.21 | TheFly | Previous targets (1) |
Mohit Bansal Wells Fargo | 0% 0/2 | over 1 year ago | $140 64.84% upside | $131.05 | StreetInsider | Previous targets (1) |
Evan David Seigerman BMO Capital | 33.33% 1/3 | over 1 year ago | $148 74.26% upside | $127.71 | StreetInsider | Previous targets (2) |
Unknown Truist Financial | N/A | over 1 year ago | $142 67.19% upside | $130.81 | StreetInsider | N/A |
Mohit Bansal Wells Fargo | 0% 0/2 | over 1 year ago | $135 58.95% upside | $130.19 | StreetInsider | Previous targets (1) |
Akash Tewari Jefferies | 0% 0/3 | over 1 year ago | $145 70.72% upside | $130.18 | StreetInsider | Previous targets (2) |
Evan David Seigerman Loop Capital Markets | 0% 0/1 | almost 2 years ago | $132 55.42% upside | $101.44 | Benzinga | Previous targets (0) |
Jay Olson Oppenheimer | 0% 0/1 | over 2 years ago | $294 246.16% upside | $112.68 | Benzinga | Previous targets (0) |
Unknown Wells Fargo | N/A | over 2 years ago | $120 41.29% upside | $103.28 | Benzinga | N/A |
Unknown Morgan Stanley | N/A | over 2 years ago | $99 16.56% upside | $103.46 | Benzinga | N/A |
Unknown Wells Fargo | N/A | over 2 years ago | $125 47.18% upside | $110.62 | Benzinga | N/A |
Unknown Cantor Fitzgerald | N/A | almost 3 years ago | $135 58.95% upside | $109.2 | Benzinga | N/A |
Unknown Credit Suisse | N/A | almost 3 years ago | $120 41.29% upside | $102.31 | Benzinga | N/A |
Unknown Leerink Partners | N/A | almost 3 years ago | $110 29.51% upside | $86.64 | Benzinga | N/A |
Unknown Leerink Partners | N/A | about 3 years ago | $109 28.34% upside | $87.34 | Benzinga | N/A |
Unknown Leerink Partners | N/A | about 3 years ago | $105 23.63% upside | $89.94 | Benzinga | N/A |
Unknown Barclays | N/A | about 3 years ago | $101 18.92% upside | $88.63 | Benzinga | N/A |
Unknown Morgan Stanley | N/A | about 3 years ago | $92 8.32% upside | $89.26 | Benzinga | N/A |
Unknown UBS | N/A | about 3 years ago | $98 15.38% upside | $94.35 | Benzinga | N/A |
Unknown Atlantic Equities | N/A | about 3 years ago | $110 29.51% upside | $93.6 | Benzinga | N/A |
Unknown Morgan Stanley | N/A | about 3 years ago | $88 3.61% upside | $93.01 | Benzinga | N/A |
Unknown Morgan Stanley | N/A | over 3 years ago | $87 2.43% upside | $88.62 | Benzinga | N/A |
Unknown Leerink Partners | N/A | over 3 years ago | $102 20.09% upside | $88.58 | Benzinga | N/A |
Unknown Leerink Partners | N/A | over 3 years ago | $97 14.21% upside | $86.46 | Benzinga | N/A |
Carter Gould Barclays | 33.33% 1/3 | over 3 years ago | $97 14.21% upside | $86.91 | Pulse 2.0 | Previous targets (2) |
Terence Flynn Morgan Stanley | 100% 1/1 | over 3 years ago | $80 -5.80% downside | $86.63 | Pulse 2.0 | Previous targets (0) |
Evan David Seigerman BMO Capital | 33.33% 1/3 | over 3 years ago | $87 2.43% upside | $87.68 | Pulse 2.0 | Previous targets (2) |
Chris Shibutani Goldman Sachs | 100% 1/1 | almost 4 years ago | $93 9.50% upside | $75.02 | TheFly | Previous targets (0) |
Colin Bristow UBS | 50% 1/2 | almost 4 years ago | $76 -10.51% downside | $72.09 | TheFly | Previous targets (1) |
Andrew Baum Citigroup | 100% 1/1 | almost 4 years ago | $85 0.08% upside | $73.53 | MarketWatch | Previous targets (0) |
David Toung Argus Research | 100% 1/1 | almost 4 years ago | $110 29.51% upside | $86.25 | TheFly | Previous targets (0) |
Carter Gould Barclays | 33.33% 1/3 | almost 4 years ago | $94 10.67% upside | $86.25 | StreetInsider | Previous targets (2) |
Tim Anderson Wolfe Research | 100% 1/1 | almost 4 years ago | $94 10.67% upside | $86.45 | StreetInsider | Previous targets (0) |
Geoff Meacham Bank of America Securities | 50% 1/2 | almost 4 years ago | $86 1.25% upside | $86.45 | StreetInsider | Previous targets (1) |
Daniel Busby RBC Capital | 100% 1/1 | about 4 years ago | $80 -5.80% downside | $74.86 | TipRanks | Previous targets (0) |
Merck & Co. Financial Estimates
Merck & Co. Revenue Estimates
Merck & Co. EBITDA Estimates
Merck & Co. Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $48.70B N/A | $59.28B 21.72% | $60.11B 1.40% | Avg: $68.67B Low: $66.20B High: $71.65B avg. 14.24% | Avg: $72.75B Low: $70.93B High: $74.69B avg. 5.94% | Avg: $75.44B Low: $73.55B High: $77.45B avg. 3.69% | Avg: $78.16B Low: $76.20B High: $80.23B avg. 3.59% |
Net Income
% change YoY
| $13.04B N/A | $14.51B 11.26% | $365M -97.48% | Avg: $22.24B Low: $18.74B High: $24.98B avg. 5995.05% | Avg: $24.79B Low: $20.09B High: $28.38B avg. 11.44% | Avg: $29.24B Low: $28.29B High: $30.25B avg. 17.95% | Avg: $30.92B Low: $29.91B High: $31.99B avg. 5.74% |
EBITDA
% change YoY
| $13.86B N/A | $18.61B 34.33% | $6.90B -62.90% | Avg: $16.16B Low: $15.58B High: $16.86B avg. 134.03% | Avg: $17.12B Low: $16.69B High: $17.58B avg. 5.94% | Avg: $17.75B Low: $17.31B High: $18.23B avg. 3.69% | Avg: $18.39B Low: $17.93B High: $18.88B avg. 3.59% |
EPS
% change YoY
| $5.16 N/A | $5.73 11.04% | $0.14 -97.55% | Avg: $8.94 Low: $7.36 High: $9.81 avg. 6283.15% | Avg: $9.76 Low: $7.89 High: $11.14 avg. 9.24% | Avg: $11.48 Low: $11.11 High: $11.88 avg. 17.61% | Avg: $12.14 Low: $11.75 High: $12.56 avg. 5.74% |
Operating Expenses
% change YoY
| $21.87B N/A | $23.59B 7.82% | $40.91B 73.42% | Avg: $13.53B Low: $13.04B High: $14.12B avg. -66.91% | Avg: $14.33B Low: $13.97B High: $14.71B avg. 5.94% | Avg: $14.86B Low: $14.49B High: $15.26B avg. 3.69% | Avg: $15.40B Low: $15.01B High: $15.81B avg. 3.59% |
FAQ
What is Merck & Co. stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 1507.54% in 2025-2028.
We have gathered data from 14 analysts. Their low estimate is 18.74B, average is 22.24B and high is 24.98B.
What is Merck & Co. stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 6.86% in 2025-2028.
We have gathered data from 17 analysts. Their low revenue estimate is $66.20B, average is $68.67B and high is $71.65B.
What is Merck & Co. stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 1578.93% in 2025-2028.
We have gathered data from 14 analysts. Their low earnings per share estimate is $7.36, average is $8.94 and high is $9.81.
What is the best performing analyst?
In the last twelve months 5 analysts have been covering Merck & Co. stock. The most successful analyst is Courtney Breen.